Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia

Leukemia and Lymphoma

Volumn 52, Issue 2, 2011, Pages 325-327

  Piccaluga, Pier Paolo ^a   Arpinati, Mario ^a   Candoni, Anna ^b   Laterza, Claudio ^a   Paolini, Stefania ^a   Gazzola, Anna ^a   Sabattini, Elena ^a   Visani, Giuseppe ^c   Pileri, Stefano A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c SAN SALVATORE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BLINATUMOMAB; EPRATUZUMAB; GEMTUZUMAB OZOGAMICIN; INOTUZUMAB OZOGAMICIN; RITUXIMAB;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CANCER PATIENT; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD20; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; YOUNG ADULT;

EID: 79551641737     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.529206     Document Type: Letter

References (21)

1. Hoelzer D, Gokbuget N, Ottmann O, et al. Acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2002:162-192.
2. Béné MC, Kolopp Sarda MN, El Kaissouni J, De March Kennel A, Molé C, Kohler C, Faure GC. Automated cell count in flow cytometry: a valuable tool to assess CD4 absolute levels in peripheral blood. Am J Clin Pathol 1998;110:321-26.
3. Borowitz M, Chan J. B lymphoblastic leukaemia/lymphoma, not otherwise specified. In: Swerdlow S, Campo E, Harris NL, et al., editors. WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 168-170.
4. Gokbuget N, Hoelzer D. Novel antibody-based therapy for acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2006;19:701-713. (Pubitemid 44418029)
5. Tallman MS. Monoclonal antibody therapies in leukemias. Semin Hematol 2002;39:12-19.
6. Hrusak O, Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 2002;16: 1233-1258.
7. Chevallier P, Robillard N, Houille G, et al. Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases. Leukemia 2009;23: 806-807.
8. Borowitz M, Chan J. B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities. In: Swerdlow S, Campo E, Harris NL, et al., editors. WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 171-175.
9. Borowitz M, Chan J. T lymphoblastic leukaemia/lymphoma. In: Swerdlow S, Campo E, Harris NL, et al., editors. WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 176-178.
10. Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosomenegative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010;28:3880-3889.
11. Piccaluga PP, Paolini S, Martinelli G. Tyrosine kinase inhibitors for the treatment of Philadelphia hromosomepositive adult acute lymphoblastic leukemia. Cancer 2007; 110:1178-1186.
12. Golay J, Di Gaetano N, Amico D, et al. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. Br J Haematol 2005;128:310-317.
13. Piccaluga PP, Martinelli G, Malagola M, et al. Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. Leuk Lymphoma 2004;45:731-733.
14. Laporte JP, Isnard F, Garderet L, Fouillard L, Gorin NC. Remission of adult acute lymphocytic leukaemia with alemtuzumab. Leukemia 2004;18:1557-1558.
15. Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma 2009;50:886-891.
16. d'Argouges S, Wissing S, Brandl C, et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res 2009;33:465-473.
17. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974-977.
18. Tsimberidou AM, Giles FJ, Estey E, O'Brien S, Keating MJ, Kantarjian HM. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 2006;132:398-409.
19. Chevallier P, Mahe B, Garand R, Talmant P, Harousseau JL, Delaunay J. Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression. Int J Hematol 2008;88:209-211.
20. Cheung KC, Wong LG, Yeung YM. Treatment of CD33 positive refractory acute lymphoblastic leukemia with xylotarg. Leuk Lymphoma 2008;49:596-597.
21. Nijmeijer BA, van Schie ML, Halkes CJ, Griffioen M, Willemze R, Falkenburg JH. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL. Blood 2010 Sep 15. [Epub ahead of print].